IN2014MN02562A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02562A
IN2014MN02562A IN2562MUN2014A IN2014MN02562A IN 2014MN02562 A IN2014MN02562 A IN 2014MN02562A IN 2562MUN2014 A IN2562MUN2014 A IN 2562MUN2014A IN 2014MN02562 A IN2014MN02562 A IN 2014MN02562A
Authority
IN
India
Prior art keywords
alkyl
con
heterocyclyl
further described
substituted
Prior art date
Application number
Other languages
English (en)
Inventor
Johann Leban
Mirko Zaja
Original Assignee
4Sc Discovery Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Discovery Gmbh filed Critical 4Sc Discovery Gmbh
Publication of IN2014MN02562A publication Critical patent/IN2014MN02562A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
IN2562MUN2014 2012-06-27 2013-06-27 IN2014MN02562A (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261664936P 2012-06-27 2012-06-27
EP12174669 2012-07-02
PCT/EP2013/063537 WO2014001464A1 (en) 2012-06-27 2013-06-27 Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders

Publications (1)

Publication Number Publication Date
IN2014MN02562A true IN2014MN02562A (hr) 2015-07-24

Family

ID=49782305

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2562MUN2014 IN2014MN02562A (hr) 2012-06-27 2013-06-27

Country Status (19)

Country Link
US (2) US9580438B2 (hr)
EP (1) EP2867237A1 (hr)
JP (2) JP6272846B2 (hr)
KR (1) KR102155559B1 (hr)
CN (1) CN104540831B (hr)
AU (2) AU2013283318B2 (hr)
BR (1) BR112014032581A8 (hr)
CA (1) CA2877589C (hr)
EA (1) EA029718B1 (hr)
HK (1) HK1204474A1 (hr)
IL (1) IL236463A0 (hr)
IN (1) IN2014MN02562A (hr)
MX (1) MX350418B (hr)
MY (1) MY167785A (hr)
NZ (1) NZ702618A (hr)
SG (1) SG11201408617PA (hr)
UA (1) UA116541C2 (hr)
WO (1) WO2014001464A1 (hr)
ZA (1) ZA201409194B (hr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116541C2 (uk) * 2012-06-27 2018-04-10 4Ск Діскавері Гмбх Біфтордіоксаланамінобензімідазольні інгібітори кінази для лікування злоякісного новоутворення, аутоімунного запалення і порушень цнс
CN106661027B (zh) 2014-03-20 2019-12-24 卡佩拉医疗公司 苯并咪唑衍生物作为erbb酪氨酸激酶抑制剂用于治疗癌症
AU2015231202B9 (en) 2014-03-20 2019-10-24 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
CN107108581B (zh) 2014-08-21 2020-06-23 百时美施贵宝公司 作为强效rock抑制剂的回接苯甲酰胺衍生物
WO2017013210A1 (en) * 2015-07-21 2017-01-26 4Sc Ag Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds
US10590108B2 (en) 2015-09-23 2020-03-17 Capella Therapeutics, Inc. Benzimidazoles for use in the treatment of cancer and inflammatory diseases
CR20200045A (es) 2016-04-07 2020-03-11 Glaxosmithkline Ip Dev Ltd AMIDAS HETEROCÍCLICAS ÚTILES COMO MODULADORES DE PROTEÍNAS (Divisional 2018-0472)
AU2018355487B2 (en) 2017-10-27 2023-09-21 Shanghai Yao Yuan Biotechnology Co., Ltd. Compositions and methods of modulating the immune response by activating alpha protein kinase 1
AU2019339186A1 (en) 2018-09-13 2021-03-25 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
CN109020990A (zh) * 2018-09-20 2018-12-18 广西壮族自治区药用植物园 苯基苯并呋喃化合物、及其制备方法、组合物和医药用途
KR102119150B1 (ko) * 2018-10-23 2020-06-04 한국원자력의학원 N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
WO2020132582A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting agonists and uses thereof
EP4173639A4 (en) 2020-06-26 2024-03-13 Raqualia Pharma Inc METHOD FOR SELECTING A CANCER PATIENT WITH EFFECT OF COMBINATION THERAPY WITH RETINOID AND CANCER TREATMENT
CN116942819A (zh) * 2023-04-24 2023-10-27 珠海市人民医院 微管相关丝氨酸/苏氨酸样激酶抑制剂在制备治疗肿瘤的药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167569A (en) 1976-12-09 1979-09-11 Imperial Chemical Industries Limited Pyrimido[1,2-a ]benzimidazole derivatives
WO2003030902A1 (en) 2001-10-09 2003-04-17 Tularik Inc. Imidazole derivates as anti-inflammatory agents
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
EP1388341A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
JO2724B1 (en) 2004-08-19 2013-09-15 افينتس فارماسوتيكالز انك 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
US7541367B2 (en) 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
EP1957078B1 (en) 2005-12-02 2013-08-28 Bayer HealthCare, LLC Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
FR2918061B1 (fr) 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
WO2009047163A1 (en) 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
IN2012DN03312A (hr) * 2009-10-22 2015-10-23 Fibrotech Therapeutics Pty Ltd
UA116541C2 (uk) * 2012-06-27 2018-04-10 4Ск Діскавері Гмбх Біфтордіоксаланамінобензімідазольні інгібітори кінази для лікування злоякісного новоутворення, аутоімунного запалення і порушень цнс

Also Published As

Publication number Publication date
HK1204474A1 (en) 2015-11-20
MY167785A (en) 2018-09-25
US20150158878A1 (en) 2015-06-11
AU2013283318A1 (en) 2015-01-22
EA029718B1 (ru) 2018-05-31
SG11201408617PA (en) 2015-01-29
AU2013283318B2 (en) 2017-11-23
ZA201409194B (en) 2017-08-30
WO2014001464A1 (en) 2014-01-03
EA201500050A1 (ru) 2015-09-30
CN104540831B (zh) 2017-11-07
CN104540831A (zh) 2015-04-22
EP2867237A1 (en) 2015-05-06
CA2877589C (en) 2019-11-26
AU2018201275A1 (en) 2018-03-15
CA2877589A1 (en) 2014-01-03
JP2018076360A (ja) 2018-05-17
JP2015525742A (ja) 2015-09-07
MX2014015938A (es) 2015-07-21
UA116541C2 (uk) 2018-04-10
BR112014032581A8 (pt) 2018-08-14
IL236463A0 (en) 2015-02-26
JP6272846B2 (ja) 2018-01-31
KR20150037877A (ko) 2015-04-08
BR112014032581A2 (pt) 2017-06-27
NZ702618A (en) 2016-12-23
KR102155559B1 (ko) 2020-09-15
US9580438B2 (en) 2017-02-28
US20170240556A1 (en) 2017-08-24
MX350418B (es) 2017-09-06

Similar Documents

Publication Publication Date Title
IN2014MN02562A (hr)
EP2581376A4 (en) MATRIC ACID / MATRIN DERIVATIVES AND MANUFACTURING METHOD AND USES THEREOF
ATE517882T1 (de) Chinolinderivate
PH12014502524B1 (en) Carboxylic acid compounds
UA109698C2 (xx) Похідні азаіндазолу або діазаіндазолу як медикамент
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
IN2014MN00988A (hr)
MD20140063A2 (ro) Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
EP2650293A8 (en) [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
EA201200318A1 (ru) Гетероциклические оксимы
WO2012173682A3 (en) Compounds and methods for the treatment of isocitrate dehydrognase related diseases
IN2015DN01119A (hr)
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
IN2012DN02502A (hr)
WO2011123536A8 (en) Polycyclic tetracycline compounds
CA2920410C (en) Thienopiperidine derivative and use thereof
HK1190643A1 (zh) 用於胃腸外施用的吡咯藥物製劑及其製備方法和治療對吡咯化合物敏感的疾病的使用方法
IN2014CN03854A (hr)
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
IN2013DN02555A (hr)
IN2014DN11023A (hr)
IN2014KN01113A (hr)